- Published on
KembaraXtra-Medicine – Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a biologically based neurodevelopmental disorder that includes a range of developmental disabilities. It is defined by early-appearing social-communication difficulties and restricted, repetitive patterns of behavior, interests, or activities. ASD describes a constellation of social communication deficits and repetitive sensorimotor behaviors, often with a strong genetic component and sometimes other identifiable causes. Outcomes today are generally better than decades ago, with more individuals able to communicate, learn, and live in the community, though many still require ongoing support into adulthood. Clinicians play an important role by helping families access evaluations, referrals, and community resources, and by anticipating major transitions such as starting school and moving into adult services.
Diagnosis is based on DSM-5-TR or ICD-11 criteria. DSM-5-TR requires persistent deficits in social communication and social interaction across multiple contexts (including social-emotional reciprocity, nonverbal communication, and relationships) plus restricted/repetitive patterns of behavior (such as stereotyped movements or speech, insistence on sameness, restricted interests, and sensory hyper- or hyporeactivity). ASD can be further described by whether intellectual disability, language impairment, medical/genetic conditions, or catatonia are present. Comorbid intellectual disability, neurologic/medical problems, and psychiatric disorders are common, and symptom severity varies widely between individuals.
ASD affects an estimated 1% to 3% of children in the United States, with prevalence often described as approximately 1 in 40 children. Rates have increased over recent decades, but it is unclear whether this reflects broader criteria, increased awareness and diagnostic accuracy, or a true rise in frequency. ASD is more common in males, with an estimated male-to-female ratio of about 3:1. Most children are identified by age 4, often because of delayed communication milestones, though presentation and timing of diagnosis can vary depending on language, cognition, and adaptive functioning.
Risk factors include several prenatal and perinatal factors such as hypoxia-related obstetric complications, prenatal infections, maternal use of certain medications (notably valproic acid), maternal health conditions (diabetes, hypertension, obesity, preeclampsia), advanced parental age, multiple gestation, prematurity, and congenital sensory deficits. Environmental exposures have also been associated in some studies, including significant air pollution exposure during pregnancy and early life and heavy maternal smoking. ASD is highly heritable, with an estimated heritability around 80%. Concordance rates rise with genetic relatedness, and research has identified many genetic contributors including polygenic risk and rare variants such as copy number variants. Neurobiologic studies show brain differences in some individuals with ASD, including atypical connectivity and cortical structural differences, but these findings are not diagnostic.
Clinically, ASD is often described by a triad: impairment in social interaction, atypical verbal and nonverbal communication, and repetitive or unusual behaviors. Social difficulties can include poor social-emotional reciprocity and reduced shared attention. Communication may be affected through limited gestures, reduced facial expression, or difficulty using and interpreting nonverbal signals. Repetitive features may include stereotyped movements (such as hand flapping or rocking), repetitive speech (including echolalia), and strong preferences for sameness or routine. Sensory differences are common, including hypersensitivity to sound, touch, or smells, or hyposensitivity such as unusually high pain tolerance. Catatonia can appear in up to 20% of adolescents and adults with ASD.
Many conditions and syndromes are associated with ASD. Approximately 20% to 50% of individuals have intellectual disability, about 50% have ADHD, around 25% have an associated genetic syndrome, and roughly 12% have epilepsy. Examples of associated syndromes include fragile X syndrome, tuberous sclerosis, Angelman syndrome, Rett syndrome, Down syndrome, and DiGeorge syndrome, among others.
The differential diagnosis includes other psychiatric and neurodevelopmental disorders that may share overlapping features, such as ADHD, Tourette syndrome, selective mutism, catatonia, social anxiety, obsessive-compulsive disorder, language disorders, stereotypic movement disorder, and intellectual disability. Social (pragmatic) communication disorder is an important distinction because it involves social communication deficits without the restricted/repetitive behaviors required for ASD. Attachment disorders can also mimic aspects of ASD, particularly in children with histories of early neglect.
Workup focuses on confirming diagnosis and identifying contributing or associated medical conditions, including genetic syndromes. “Red flags” in early social communication should prompt evaluation, such as no vocalizations by 6 months, no consonant babbling by 12 months, no gestures by 12 months, no spontaneous single words by 16 months, no spontaneous phrases by 24 months, or any loss of previously acquired social-communication skills. The American Academy of Pediatrics and the CDC recommend formal ASD screening at 18 and 24 months. Gold-standard assessment includes detailed developmental and family history, evaluation of intellectual/developmental functioning, direct assessment of ASD symptoms, and measurement of adaptive functioning, with additional language, neuropsychologic, motor, or psychiatric assessments as needed.
Laboratory testing may include newborn screening review (such as PKU), lead screening, hearing assessment, and genetic testing (karyotype, chromosome microarray, and targeted DNA testing when indicated). Creatine kinase and TSH may be considered when motor concerns are present. An EEG is recommended when seizures are suspected or when there is language regression. Brain imaging is recommended if macrocephaly, microcephaly, or abnormal tone/motor findings are present.
Treatment emphasizes early and structured intervention. Nonpharmacologic therapy includes behavioral programs at home and school, applied behavioral analysis (ABA) approaches (such as Discrete Trial Training), and development-focused ABA models (such as Pivotal Response Training, Floortime, and the Early Start Denver Model). Specialized educational approaches focusing on communication and life skills (such as TEACCH) are often helpful. Cognitive-behavioral therapy can reduce anxiety in higher-functioning individuals. Family and teacher education and highly structured environments support skill-building and daily functioning.
Medication does not “cure” ASD, but can reduce specific target symptoms. Risperidone and aripiprazole are FDA-approved for managing irritability associated with ASD. Other medications are used off-label depending on symptoms, including SSRIs or atypical antipsychotics for obsessive or ritualistic behaviors, atypical antipsychotics and other agents for aggression or self-injury, stimulants or alpha-2 agonists for hyperactivity/inattention, and SSRIs or other agents for anxiety or depression. Catatonia is treated with lorazepam and sometimes electroconvulsive therapy, and antipsychotics should be avoided in catatonia because they can worsen it. Complementary approaches have limited evidence overall, though melatonin has preliminary evidence for sleep difficulties.
Most individuals with ASD require some level of support as adults. DSM-5-TR describes severity levels based on support needs, from Level 1 (requiring support) to Level 3 (requiring very substantial support). Better outcomes are linked to early identification and intervention, development of functional spoken language, and capacity for inclusion with typical peers. Poorer outcomes are associated with lack of joint attention by age 4, absence of functional speech by age 5, intellectual disability, seizures, significant comorbid medical or psychiatric conditions, and pervasive social disengagement. Referrals may involve specialists for diagnosis (developmental pediatrics, child psychiatry, psychology, neurology, genetics) and therapy services (speech-language therapy, occupational therapy, behavioral therapy), as well as support for caregivers and school planning.
There is no scientific evidence linking childhood vaccination to the development of ASD. Many individuals with ASD have increased rates of medical issues such as sleep problems, gastrointestinal concerns, and oral health problems, and psychiatric comorbidities are common across the lifespan.
Autism spectrum disorder (ASD) is a biologically based neurodevelopmental disorder that includes a range of developmental disabilities. It is defined by early-appearing social-communication difficulties and restricted, repetitive patterns of behavior, interests, or activities. ASD describes a constellation of social communication deficits and repetitive sensorimotor behaviors, often with a strong genetic component and sometimes other identifiable causes. Outcomes today are generally better than decades ago, with more individuals able to communicate, learn, and live in the community, though many still require ongoing support into adulthood. Clinicians play an important role by helping families access evaluations, referrals, and community resources, and by anticipating major transitions such as starting school and moving into adult services.
Diagnosis is based on DSM-5-TR or ICD-11 criteria. DSM-5-TR requires persistent deficits in social communication and social interaction across multiple contexts (including social-emotional reciprocity, nonverbal communication, and relationships) plus restricted/repetitive patterns of behavior (such as stereotyped movements or speech, insistence on sameness, restricted interests, and sensory hyper- or hyporeactivity). ASD can be further described by whether intellectual disability, language impairment, medical/genetic conditions, or catatonia are present. Comorbid intellectual disability, neurologic/medical problems, and psychiatric disorders are common, and symptom severity varies widely between individuals.
ASD affects an estimated 1% to 3% of children in the United States, with prevalence often described as approximately 1 in 40 children. Rates have increased over recent decades, but it is unclear whether this reflects broader criteria, increased awareness and diagnostic accuracy, or a true rise in frequency. ASD is more common in males, with an estimated male-to-female ratio of about 3:1. Most children are identified by age 4, often because of delayed communication milestones, though presentation and timing of diagnosis can vary depending on language, cognition, and adaptive functioning.
Risk factors include several prenatal and perinatal factors such as hypoxia-related obstetric complications, prenatal infections, maternal use of certain medications (notably valproic acid), maternal health conditions (diabetes, hypertension, obesity, preeclampsia), advanced parental age, multiple gestation, prematurity, and congenital sensory deficits. Environmental exposures have also been associated in some studies, including significant air pollution exposure during pregnancy and early life and heavy maternal smoking. ASD is highly heritable, with an estimated heritability around 80%. Concordance rates rise with genetic relatedness, and research has identified many genetic contributors including polygenic risk and rare variants such as copy number variants. Neurobiologic studies show brain differences in some individuals with ASD, including atypical connectivity and cortical structural differences, but these findings are not diagnostic.
Clinically, ASD is often described by a triad: impairment in social interaction, atypical verbal and nonverbal communication, and repetitive or unusual behaviors. Social difficulties can include poor social-emotional reciprocity and reduced shared attention. Communication may be affected through limited gestures, reduced facial expression, or difficulty using and interpreting nonverbal signals. Repetitive features may include stereotyped movements (such as hand flapping or rocking), repetitive speech (including echolalia), and strong preferences for sameness or routine. Sensory differences are common, including hypersensitivity to sound, touch, or smells, or hyposensitivity such as unusually high pain tolerance. Catatonia can appear in up to 20% of adolescents and adults with ASD.
Many conditions and syndromes are associated with ASD. Approximately 20% to 50% of individuals have intellectual disability, about 50% have ADHD, around 25% have an associated genetic syndrome, and roughly 12% have epilepsy. Examples of associated syndromes include fragile X syndrome, tuberous sclerosis, Angelman syndrome, Rett syndrome, Down syndrome, and DiGeorge syndrome, among others.
The differential diagnosis includes other psychiatric and neurodevelopmental disorders that may share overlapping features, such as ADHD, Tourette syndrome, selective mutism, catatonia, social anxiety, obsessive-compulsive disorder, language disorders, stereotypic movement disorder, and intellectual disability. Social (pragmatic) communication disorder is an important distinction because it involves social communication deficits without the restricted/repetitive behaviors required for ASD. Attachment disorders can also mimic aspects of ASD, particularly in children with histories of early neglect.
Workup focuses on confirming diagnosis and identifying contributing or associated medical conditions, including genetic syndromes. “Red flags” in early social communication should prompt evaluation, such as no vocalizations by 6 months, no consonant babbling by 12 months, no gestures by 12 months, no spontaneous single words by 16 months, no spontaneous phrases by 24 months, or any loss of previously acquired social-communication skills. The American Academy of Pediatrics and the CDC recommend formal ASD screening at 18 and 24 months. Gold-standard assessment includes detailed developmental and family history, evaluation of intellectual/developmental functioning, direct assessment of ASD symptoms, and measurement of adaptive functioning, with additional language, neuropsychologic, motor, or psychiatric assessments as needed.
Laboratory testing may include newborn screening review (such as PKU), lead screening, hearing assessment, and genetic testing (karyotype, chromosome microarray, and targeted DNA testing when indicated). Creatine kinase and TSH may be considered when motor concerns are present. An EEG is recommended when seizures are suspected or when there is language regression. Brain imaging is recommended if macrocephaly, microcephaly, or abnormal tone/motor findings are present.
Treatment emphasizes early and structured intervention. Nonpharmacologic therapy includes behavioral programs at home and school, applied behavioral analysis (ABA) approaches (such as Discrete Trial Training), and development-focused ABA models (such as Pivotal Response Training, Floortime, and the Early Start Denver Model). Specialized educational approaches focusing on communication and life skills (such as TEACCH) are often helpful. Cognitive-behavioral therapy can reduce anxiety in higher-functioning individuals. Family and teacher education and highly structured environments support skill-building and daily functioning.
Medication does not “cure” ASD, but can reduce specific target symptoms. Risperidone and aripiprazole are FDA-approved for managing irritability associated with ASD. Other medications are used off-label depending on symptoms, including SSRIs or atypical antipsychotics for obsessive or ritualistic behaviors, atypical antipsychotics and other agents for aggression or self-injury, stimulants or alpha-2 agonists for hyperactivity/inattention, and SSRIs or other agents for anxiety or depression. Catatonia is treated with lorazepam and sometimes electroconvulsive therapy, and antipsychotics should be avoided in catatonia because they can worsen it. Complementary approaches have limited evidence overall, though melatonin has preliminary evidence for sleep difficulties.
Most individuals with ASD require some level of support as adults. DSM-5-TR describes severity levels based on support needs, from Level 1 (requiring support) to Level 3 (requiring very substantial support). Better outcomes are linked to early identification and intervention, development of functional spoken language, and capacity for inclusion with typical peers. Poorer outcomes are associated with lack of joint attention by age 4, absence of functional speech by age 5, intellectual disability, seizures, significant comorbid medical or psychiatric conditions, and pervasive social disengagement. Referrals may involve specialists for diagnosis (developmental pediatrics, child psychiatry, psychology, neurology, genetics) and therapy services (speech-language therapy, occupational therapy, behavioral therapy), as well as support for caregivers and school planning.
There is no scientific evidence linking childhood vaccination to the development of ASD. Many individuals with ASD have increased rates of medical issues such as sleep problems, gastrointestinal concerns, and oral health problems, and psychiatric comorbidities are common across the lifespan.
0 Comments
